Tag Archive | "cetuximab"
Pitt researchers receive patent for new head and neck cancer treatment
Source: www.healthcanal.com Author: staff Researchers from the University of Pittsburgh School of Medicine have been awarded a patent from the U.S. Patent and Trademark Office for the development of a new DNA therapy for head and neck cancers. The therapy targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many types of [...]
Continue reading...Idera obtains clinical milestone under collaboration with Merck
Friday, January 22, 2010
Source: www.tradingmarkets.com Author: staff Idera Pharmaceuticals, a biotechnology company, has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase II trial by Merck KGaA of EMD 1201081, a novel agonist of toll-like receptor 9 (TLR9), in combination with cetuximab in second-line cetuximab-naive [...]
Continue reading...Oropharyngeal cancer, human papilloma virus, and clinical trials
Wednesday, December 30, 2009
Source: Journal of Clinical Oncology, Vol 28, No 1 (January 1), 2010: pp. 1-3 Author: Danny Rischin As advances in our understanding of the molecular biology of cancer have evolved in recent years, cancers that were once considered to be relatively homogeneous diseases are now being recognized as comprising distinct subtypes. These subtypes may differ in etiology, [...]
Continue reading...Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer
Tuesday, November 17, 2009
Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study were [...]
Continue reading...Erbitux recognized by ASCO as a 2009 major cancer advance as first SCCHN treatment to improve survival in 30 years
Monday, November 16, 2009
Source: www.vwd.de Author: press release The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with first-line recurrent and/or metastatic squamous [...]
Continue reading...Report highlights cancer advances
Tuesday, November 10, 2009
Source: www.medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today As the war on cancer enters its fifth decade, 51 studies stood out as examples of progress that occurred in the past year, as determined by the American Society of Clinical Oncology (ASCO) and reported in “Clinical Cancer Advances 2009.” Reflecting input from specialists throughout the field, the ASCO [...]
Continue reading...Cetuximab continues to increase survival in patients with head and neck cancer for up to 5 years
Saturday, November 7, 2009
Source: www.docguide.com Author: staff Adding cetuximab to radiation therapy prolongs survival in patients with locally advanced head and neck cancer compared with radiotherapy alone, and this improvement persists for up to 5 years. As such, this combined treatment should be considered as a standard option for patients with advanced head and neck cancer, according to a study published [...]
Continue reading...YM Biosciences reports positive nimotuzumab four-year survival data
Tuesday, November 3, 2009
Source: www.reuters.com Author: press release YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that an oral presentation at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2009 Annual Meeting reported positive 48-month survival data for its EGFR-targeting antibody, [...]
Continue reading...DNA therapy for head and neck cancer
Tuesday, June 2, 2009
Source: Nature Reviews Clinical Oncology 6, 302 (June 2009) Author: Mandy Aujla Researchers have developed an antisense EGFR sequence to target EGFR, and found that this approach was safe and effective in patients with advanced squamous-cell carcinoma of the head and neck. Standard treatment for this type of cancer is suboptimal. Various drugs have been developed to block [...]
Continue reading...Monoclonal Antibody Drugs for Cancer Treatment
Sunday, April 5, 2009
Source: www.newswise.com Author: staff The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects. For several types of cancer, monoclonal antibodies have already offered this advantage [...]
Continue reading...- Samuel Broder: Why Isn't There a Gardasil for Men?
- Snus news & other tobacco products
- High dosage brachytherapy obtains excellent results in head and neck tumors
- A vaccine debate once focused on sex shifts as boys join the target market
- Consistent evidence to support the use of xylitol- and sorbitol-containing chewing gum to prevent dental caries
- Bill would bar sales of dissolvable tobacco
- R. J. Reynolds introducing 'dissolvable' tobacco
- Smoking debate has become nicotine-delivery debate
- Israeli study sees link between oral cancer, cell phones
- Periodontitis associated with fourfold increased risk for squamous cell carcinoma of the head and neck
- hilllaguna: Negating that nicotine replacement therapies are p...
- OC Advocate: It comes a little surprise that this "test" which ...
- hilllaguna: By world medical treatment standards a diagnosis t...
- Oral Cancer Foundation News Team: After sending this retrospective look to major can...
- hilllaguna: The mathematical probably that you have been expos...
- Why men’s health is a feminist issue
- BT Pharma secures EUR 13.1million (USD 17.7 million) in capital funding and changes its name to Genticel
- Cancer survivor tells his experience with smokeless tobacco
- Mayo oral cancer study shows full tumor genome
- Viagra, Cialis do more than arouse
- Avoid incense
- Transoral robotic surgery showed good oncologic, functional outcomes
- Prolonged treatment delay did not affect outcomes in SCCHN
- Instant screening device is the best defense for detecting deadly oral cancer
- New technology helps those affected by HPV
Follow OCF on these social networking sites connect to us, get involved, spread the knowledge, help the cause, change the world.
Sunday, January 31, 2010
0 Comments